Durie, Brian G. M.
Kumar, Shaji K.
Ammann, Eric M.
Fu, Alex Z.
Kaila, Shuchita
Lam, Annette
Usmani, Saad Z.
Facon, Thierry
Funding for this research was provided by:
Janssen Global Services, LLC
Article History
Received: 1 December 2023
Accepted: 29 January 2024
First Online: 18 March 2024
Declarations
:
: Brian G.M. Durie is a consultant for Amgen, Celgene, Johnson & Johnson, and Takeda. Shaji K. Kumar received research funding from AbbVie, Allogene, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen, GSK, Janssen, Novartis, Roche-Genentech, Takeda, Regeneron, and Molecular Templates; served as a consultant or on an advisory board (with no personal payments) for AbbVie, Amgen, Bristol Myers Squibb, Janssen, Roche-Genentech, Takeda, AstraZeneca, bluebird bio, Epizyme, Secura Bio, Monte Rosa Therapeutics, Trillium, Loxo Oncology, K36, Sanofi, and Arcellx; and served as a consultant or on an advisory board (with personal payments) for Oncopeptides, BeiGene, Antengene, and GLH Pharma. Eric M. Ammann, Alex Z. Fu, Shuchita Kaila, and Annette Lam are employees of Janssen and hold equity in a publicly traded company. Saad Z. Usmani received research funding from Amgen, Array BioPharma, Bristol Myers Squibb, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDx, and Takeda; served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Edo Pharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, Secura Bio, SkylineDx, Takeda, and TeneoBio; and served as a speaker for Amgen, Bristol Myers Squibb, Janssen, and Sanofi. Thierry Facon served as a consultant or advisor for Janssen, Bristol Myers Squibb, Roche, and Takeda; and served on a speakers bureau for Janssen and Bristol Myers Squibb.
: The MAIA and SWOG S0777 trials were conducted in accordance with the principles of the Declaration of Helsinki, with study protocols approved by independent ethics committees and/or institutional review boards at each site. All patients provided written informed consent.